Table 4.
Potential renal failure metabolites.
| No | Metabolites | Level in patients | AUC |
|---|---|---|---|
| 1 | Creatinine∗ | ↑ | 0.997 |
| 2 | 1-methylhypoxanthine | ↑ | 1 |
| 3 | Beta-carboline | ↑ | 0.964 |
| 4 | Arabinofuranobiose | ↑ | 1 |
| 5 | Valdecoxib | ↓ | 1 |
| 6 | Glycerol tripropanoate | ↑ | 0.982 |
| 7 | 4-Guanidinobutanoic acid | ↑ | 1 |
| 8 | Kynurenic acid∗ | ↑ | 1 |
| 9 | Alcophosphamide | ↓ | 1 |
| 10 | 1-(Beta-D-ribofuranosyl)-1, 4-dihdronicotinamide | ↑ | 1 |
| 11 | Thelephoric acid | ↓ | 1 |
| 12 | 5′-Methylthioadenosine∗ | ↑ | 1 |
| 13 | 3-Methylglutarylcarnitine | ↑ | 1 |
| 14 | Formiminoglutamic acid | ↑ | 0.994 |
| 15 | Solacauline | ↑ | 1 |
| 16 | PC (20 : 5 (5Z, 8Z, 11Z, 17Z)/(20 : 5 (5Z, 8Z, 11Z, 17Z)) | ↑ | 1 |
| 17 | Serylalanine | ↓ | 1 |
| 18 | 5, 6-Dihydrouridine | ↑ | 1 |
| 19 | L-Beta-aspartyl-L-threonine | ↓ | 1 |
| 20 | Isoleucyl-alanine | ↑ | 0.999 |
| 21 | Beta-solamarine | ↑ | 1 |
| 22 | Presqualene diphosphate | ↑ | 1 |
| Lycoperoside D | ↑ | 1 | |
| 24 | 2-O-(6-Phospho-alpha-mannosyl)-D-glycerate | ↓ | 1 |
| 25 | 2, 8-Di-O-methylellagic acid | ↓ | 1 |
| 26 | Perlolyrine | ↑ | 0.993 |
| 27 | 3, 3′, 4′, 5, 6, 7, 8-Heptahydroxyflavone | ↓ | 1 |
| 28 | Threoninyl-aspartate | ↓ | 1 |
| 29 | Paraquat dichloride | ↓ | 1 |
| 30 | Azelaic acid | ↑ | 1 |
| 31 | (10E, 12Z)-9-HODE | ↑ | 1 |
| 32 | N-acetylglutamine | ↑ | 1 |
| 33 | 4-acetamidobutanoic acid | ↑ | 1 |
| 34 | N-acetyl-L-alanine | ↑ | 0.997 |
| 35 | Mycophenolic acid | ↑ | 1 |
| 36 | Formylanthranilic acid | ↑ | 1 |
| 37 | Trehalose | ↑ | 1 |
| 38 | Prostaglandin F3a | ↑ | 1 |
| 39 | Thymine | ↑ | 0.996 |
| 40 | Kynurenic acid | ↑ | 1 |
| 41 | Tiglic acid | ↑ | 0.975 |
| 42 | N-acetylserine | ↑ | 1 |
| 43 | Glutamyltheronine | ↓ | 1 |
| 44 | 3-methoxy-4-hydroxyphenylethyleneglycol sulfate | ↑ | 0.999 |
∗ presents the metabolites identified in kidney disease had been reported.